Plasbumin-20 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to use of albumin in volume replacement, growth in surgical procedures, trauma care expansion, liver disease management needs, hospital critical care protocols.

The growth in the forecast period can be attributed to rising geriatric population, increase in critical care admissions, expansion of recombinant albumin development, improved plasma collection infrastructure, growth of hospital based treatments. Major trends in the forecast period include rising demand for plasma derived therapies, growth of albumin use in critical care, expansion of surgical and trauma applications, increased focus on protein replacement therapy, improved plasma fractionation techniques.

The increasing prevalence of chronic diseases is expected to drive the growth of the Plasbumin-20 market in the coming years. Chronic diseases are long-term health conditions, such as heart disease, diabetes, and arthritis, that persist for a year or more, requiring ongoing medical care or limiting daily activities. The rise in chronic diseases is largely attributed to aging populations, lifestyle changes, urbanization, and genetic predispositions. As the global incidence of chronic diseases continues to grow, particularly due to aging populations and lifestyle-related factors, the demand for supportive therapies like Plasbumin-20 is expected to increase, making it a key component in managing long-term healthcare challenges. For example, in May 2025, the Centers for Disease Control and Prevention (CDC), a US-based government public health agency, reported that chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States in 2023, resulting in 141,733 deaths. In the same year, the age-adjusted prevalence of diagnosed COPD in adults aged 18 years and older was 3.8 percent. Therefore, the rise in chronic diseases is driving the Plasbumin-20 market.

The growing aging population is also expected to support the expansion of the Plasbumin-20 market. The aging population comprises individuals aged 65 and older, a demographic trend driven by longer life expectancy and declining birth rates, supported by advancements in healthcare, medical technology, and living conditions. Plasbumin-20 plays an important role for the aging population by aiding in the management of conditions associated with low protein levels, supporting better health outcomes, and enhancing resilience against age-related medical challenges such as weakened immune function and recovery from surgeries or trauma, ultimately promoting improved quality of life and independence. For instance, in January 2024, the Population Reference Bureau (PRB), a US-based nonprofit organization, projected that the number of Americans aged 65 and older would increase from 58 million in 2022 to 82 million in 2050 (a 47% rise), with their share of the total population rising from 17% to 23%. Therefore, the growing aging population is driving the Plasbumin-20 market.

The global expansion of healthcare infrastructure is further expected to propel the Plasbumin-20 market. Healthcare infrastructure includes the physical and organizational structures, facilities, resources, and systems required to deliver healthcare services to populations. Its global expansion is driven by factors such as the aging population, rising prevalence of chronic diseases, and technological advancements. Plasbumin-20, a human albumin solution derived from pooled human plasma, is used primarily for plasma protein therapy and supports improved clinical outcomes across various medical conditions. For example, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the United States had 6,129 hospitals, representing a 0.591% increase from the previous year when there were 6,093 hospitals. Therefore, the global expansion of healthcare infrastructure is driving the Plasbumin-20 market.

Major companies operating in the plasbumin-20 market are Grifols SA.

North America was the largest region in the plasbumin-20 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasbumin-20 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasbumin-20 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the plasbumin-20 market by increasing costs associated with plasma collection equipment, fractionation technologies, and sterile packaging materials. These impacts are more pronounced in regions reliant on imported plasma derivatives. North america and europe face pricing and procurement challenges in hospital settings. However, tariffs are driving investments in domestic plasma collection and processing facilities. This is improving supply security and long-term availability of albumin products.

The plasbumin-20 market research report is one of a series of new reports that provides plasbumin-20 market statistics, including plasbumin-20 industry global market size, regional shares, competitors with a plasbumin-20 market share, detailed plasbumin-20 market segments, market trends and opportunities, and any further data you may need to thrive in the plasbumin-20 industry. This plasbumin-20 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasbumin-20 is a human albumin solution derived from pooled human plasma, primarily used to restore and maintain blood volume and protein levels in patients with conditions such as hypovolemic shock, hypoproteinemia, and certain liver disorders. It is commonly employed in clinical settings to support patients undergoing surgery, managing acute liver failure, or treating other medical conditions that cause low blood protein levels.

The main forms of Plasbumin-20 are human albumin and recombinant albumin, both used to manage various medical conditions. Human albumin, derived from pooled human plasma, helps maintain blood volume and pressure and treats conditions involving low protein levels and fluid imbalance. Key indications for Plasbumin-20 include hypovolemic shock, hypoproteinemia, ARDS, cardiopulmonary bypass, and acute liver failure. It is distributed through direct sales, pharmaceutical distributors, and online channels, and is used by both adult and geriatric patients.

The Plasbumin-20 market consists of sales of Plasbumin 20% injection (100 mL) and Plasbumin 20% infusion (50 mL). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.